Literature DB >> 8785896

Minimizing complications from systemic glucocorticosteroid use.

L T Nesbitt1.   

Abstract

For proper use of systemic GCS, a basic knowledge of the normal HPA axis, as well as knowledge of the pharmacology, clinical usage guidelines, and adverse reactions of these agents is imperative. Both short-term (acute) and long-term side effects should be well known by the physician. The pros and cons of oral and parenteral therapy for various disorders and in various situations should be recognized. For long-term therapy, an intermediate-acting agent such as prednisone in single, early morning doses is most commonly used to minimize suppression of the HPA axis. Alternate-morning doses produce even less suppression if the disease process will respond. A through patient history, including general medical history and medications the patient is taking, is important to anticipate any potential problems. Weight and blood pressure should be checked initially and every 1 to 3 months thereafter. Blood glucose, electrolytes, and lipid studies, including triglycerides, should be done approximately every 6 months. An ophthalmology examination should be performed every year, and stool examination for occult blood and chest radiography can be obtained as indicated. Bone density studies might be necessary in patients who are at high risk for osteoporosis. Specific acute situations may dictate other studies. The patient on long-term GCS should be kept as active as possible, as mild-to-moderate exercise helps prevent certain side effects, such as osteoporosis. The dose of oral GCS is best given with food to prevent gastrointestinal irritation, and agents to decrease gastric acidity might be needed in certain situations. Exposure to infections should be prevented, where possible, and treatment initiated at the first sign of systemic or cutaneous infection. Pain should be evaluated early, especially abdominal pain or bone pain; MRI is indicated if aseptic necrosis of bone is suspected. Both trauma and severe sun exposure should be avoided. Consultation with other specialists is strongly recommended when the situation dictates. Diet is one of the most important strategies to minimize side effects from long-term GCS therapy. Vegetable protein should be increased in the diet, and fats and carbohydrates limited. Adequate calcium is imperative, and calcium supplementation is recommended for high-risk osteoporosis patients. Small amounts of vitamin D may be necessary to increase absorption of calcium. Restriction of sodium is also important, as is maintainance of dietary potassium. Supplemental potassium may be necessary in some patients, and a thiazide diuretic might be useful in patients with hypertension, edema, or osteoporosis. Vitamin C can be given to promote wound healing. A good doctor-patient relationship is important in managing the patient on long-term GCS. The patient must return for regular visits and be encouraged to promptly report any adverse reactions to the physician. If these criteria are maintained and the strategies noted previously are followed, problems from long-term therapy with GCS will be minimized.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8785896

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  6 in total

Review 1.  Targeting key proximal drivers of type 2 inflammation in disease.

Authors:  Namita A Gandhi; Brandy L Bennett; Neil M H Graham; Gianluca Pirozzi; Neil Stahl; George D Yancopoulos
Journal:  Nat Rev Drug Discov       Date:  2015-10-16       Impact factor: 84.694

2.  Childhood psoriasis: a study of 137 cases from central China.

Authors:  Yan Wu; Yun Lin; Hou-Jun Liu; Chang-Zheng Huang; Ai-Ping Feng; Jia-Wen Li
Journal:  World J Pediatr       Date:  2010-06-12       Impact factor: 2.764

3.  A novel therapeutic approach for reducing postoperative inflammatory complications after impacted mandibular third molar removal.

Authors:  Alaa Abdelqader Altaweel; Abd El-Hamid Gaber; Mahmoud Z Alnaffar; Abdulrahman S Almowallad; Mohamad H Almech; Abeer S Almuwallad; Rawan K Alharbi; Wasan A Arab
Journal:  Medicine (Baltimore)       Date:  2022-09-16       Impact factor: 1.817

Review 4.  Skin manifestations of Cushing's syndrome.

Authors:  Constantine A Stratakis
Journal:  Rev Endocr Metab Disord       Date:  2016-09       Impact factor: 6.514

5.  The effect of local corticosteroid or ketorolac exposure on histologic and biomechanical properties of rabbit tendon and cartilage.

Authors:  Paul S Shapiro; Rachel S Rohde; Mark I Froimson; Richard H Lash; Paul Postak; A Seth Greenwald
Journal:  Hand (N Y)       Date:  2007-05-05

6.  Glenohumeral joint injections: a review.

Authors:  Christopher Gross; Aman Dhawan; Daniel Harwood; Eric Gochanour; Anthony Romeo
Journal:  Sports Health       Date:  2013-03       Impact factor: 3.843

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.